Similar Products:
| Image | Product | Manufacturer / Marketed By | Price |
|---|---|---|---|
 | Afanat 30 mg Tablet | Natco Pharma | Ask for Price |
Xovoltib 30 mg Tablets are manufactured by Boehringer Ingelheim in Germany and contain 30 mg of Afatinib dimaleate (30mg) per tablet. Each Bottle includes 28 tablets per bottle, making Xovoltib 30 mg Tablets an effective option for Lung Cancer . Prescription Required from your healthcare provider to purchase Afatinib dimaleate (30mg) medicine. Indogenmed deals in all type of generic Afatinib dimaleate (30mg) medicine.
Targets EGFR signaling pathways involved in cancer cell growth
Part of precision oncology therapy based on tumor genetic profiling
Oral targeted therapy suitable for outpatient treatment
May help slow disease progression in certain patients with EGFR-mutated NSCLC
Used as part of modern targeted treatment strategies for lung cancer
Xovoltib (afatinib) may be prescribed for:
Metastatic non-small cell lung cancer (NSCLC) with EGFR mutation
Patients with tumors confirmed to have EGFR exon 19 deletion or exon 21 (L858R) substitution mutations
Treatment of advanced lung cancer following appropriate molecular diagnostic testing
Use is determined by an oncologist based on genetic testing results and clinical evaluation.
Afatinib works by inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and other members of the ErbB receptor family. These receptors are involved in signaling pathways that regulate cell growth, survival, and proliferation.
In certain lung cancers, mutations in the EGFR gene cause constant activation of these pathways, leading to uncontrolled tumor growth. By blocking these receptors, afatinib disrupts abnormal signaling and may reduce the ability of cancer cells to grow and spread. This targeted mechanism helps slow disease progression when the medicine is used as prescribed and monitored by an oncology specialist.
Xovoltib tablets are taken orally with water.
The medicine is usually taken once daily, unless directed otherwise by a healthcare professional.
Tablets should be taken on an empty stomach (at least 1 hour before or 2 hours after a meal).
Tablets should be swallowed whole and not crushed or chewed.
Dose adjustments may be required based on treatment tolerance and side effects.
Common side effects
Diarrhea
Skin rash or acne-like rash
Mouth sores (stomatitis)
Dry skin
Decreased appetite
Nail changes
Serious side effects
Severe diarrhea leading to dehydration
Lung inflammation (interstitial lung disease)
Liver function abnormalities
Severe skin reactions
Eye problems such as keratitis
Patients should contact their healthcare provider if severe symptoms occur.
Risk of severe diarrhea, which may lead to dehydration
Possible interstitial lung disease (lung inflammation)
Liver function abnormalities may occur
Skin reactions and photosensitivity
Eye disorders such as keratitis
Inform healthcare providers about all medications and supplements being used
Pregnancy should be avoided during treatment
Take the medicine exactly as prescribed by your oncologist
Attend scheduled medical monitoring and laboratory tests
Report symptoms such as severe diarrhea, breathing difficulty, or skin reactions
Maintain proper hydration during treatment
Inform your doctor about all medications and supplements
Do not stop treatment without consulting your healthcare provider
Afatinib has been evaluated in clinical trials for patients with EGFR mutation–positive non-small cell lung cancer. Studies such as the LUX-Lung clinical trials demonstrated improved outcomes in certain patients with EGFR-mutated NSCLC compared with earlier therapies. Based on these findings, afatinib received regulatory approvals from agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific lung cancer indications.
U.S. Food and Drug Administration (FDA) – Afatinib Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201292s019lbl.pdf
European Medicines Agency (EMA) – Afatinib Product Information
https://www.ema.europa.eu
National Cancer Institute – Afatinib Drug Information
https://www.cancer.gov
Drugs.com – Afatinib Drug Information
https://www.drugs.com
ClinicalTrials.gov – Afatinib Clinical Studies
https://clinicaltrials.gov
Related Products
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »n Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 14, 2026.n n Brain tumors, especially high-grade
READ MORE »Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.